摘要
目的探讨呼出气冷凝液、血清和组织中miRNA34a表达水平检测对非小细胞肺癌患者的应用价值。方法应用实时定量聚合酶链反应(RQ-PCR)技术检测50例病理证实为NSCLC患者的EBC、血清及其中30例手术患者癌组织、癌旁组织和50例健康人群的血清及EBC标本中miRNA34a的相对表达水平,用化学发光法检测血清癌胚抗原(CEA)和细胞角蛋白19的可溶性片段(CYFRA21-1)。结果 NSCLC患者癌组织、血清及EBC中miRA34a的相对表达量均低于对照组,差异有统计学意义(P<0.05)。晚期(Ⅲ~Ⅳ期)NSCLC患者癌组织、血清和EBC中miRNA34a的表达量低于早期(Ⅰ~Ⅱ期)患者,差异有统计学意义(P<0.05)。EBC中miRNA34a在诊断NSCLC的在灵敏度和特异度分别为:72%、78%,与血清CEA和CYFRA21-1联合应用,诊断NSCLC的在灵敏度和特异度分别为:78.3%、82.1%。结论 EBC中miRNA34a的表达量与非小细胞肺癌患者的TNM分期有关。EBC中miRNA34a与血清CEA和CYFRA21-1联合应用可提高NSCLC诊断的灵敏度和特异度。
Objective To compare the expression level of miRNA34a in exhale condensate(EBC),serum and tissues of patients with non⁃small cell lung cancer(NSCLC).To evaluate the value of EBC miRNA34a in the diagnosis of NSCLC.Methods Real⁃time quantitative polymerase chain reaction(RT⁃qPCR)technology was used to detect the EBC and serum of 50 patients with NSCLC confirmed by pathology and 30 patients with cancerous tissues and adjacent tissues from surgery and 50 healthy people.The relative expression level of miRNA34a in serum and EBC specimens was measured and analysis.Chemiluminescence was used to detect serum carcinoembryonic antigen(CEA)and soluble fragments of cytokeratin 19(CYFRA21⁃1).Results The relative expression of miRNA34a in cancer tissue,serum and EBC in NSCLC patients was lower than that in the control group(P<0.05).The expression of miRNA34a in cancer tissue,serum and EBC in advanced(stageⅢ⁃Ⅳ)non⁃small cell lung cancer was lower than that in early(stageⅠ⁃Ⅱ)lung cancer(P<0.05).The sensitivity and specificity of miRNA34a in the diagnosis of NSCLC in EBC were 72%and 82%,respectively.The sensitivity and specificity of miRNA34a、CEA and CYFRA21⁃1 in the diagnosis of NSCLC were 78.3%and 82.1%,respectively.Conclusion The expression level of miRNA34a in EBC is related to the TNM stage of non⁃small cell lung cancer patients.The combined application of miRNA34a in EBC with serum CEA and CYFRA21⁃1 can improve the sensitivity and specificity of NSCLC diagnosis.
作者
陶国华
孙苹苹
陈金亮
陈建荣
TAO Guohua;SUN Pingping;CHEN Jinliang;CHEN Jianrong(Clinical Laboratory,The First People's Hospital of Nantong,Nantong,Jiangsu,China,226001;Pneumology Department,The First People's Hospital of Nantong,Nantong,Jiangsu,China,226001)
出处
《分子诊断与治疗杂志》
2020年第12期1661-1664,1669,共5页
Journal of Molecular Diagnostics and Therapy
基金
江苏省卫生厅面上科研课题(H201454)。
